Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Post Graduate Department of Minimal Access and General Surgery, Government Medical College Srinagar, Srinagar 190010, Jammu and Kashmīr, India.
Published: October 2024
AI Article Synopsis
- The presence of liver metastasis in gastric cancer patients negatively affects the success of immunotherapy by changing the immune environment and reducing T-cell numbers.
- Research indicates that liver metastases are a significant factor for poorer results in immunotherapy, leading to shorter progression-free survival and lower response rates.
- Exploring treatments like liver-mediated radiotherapy could enhance immunotherapy outcomes by modifying the liver's immune landscape and counteracting T-cell loss.
Article Abstract
The editorial discusses the impact of liver metastasis on immunotherapy efficacy in gastric cancer (GC) patients. Liver metastasis can hinder the effectiveness of immunotherapy by altering the immune microenvironment, leading to systemic loss of T-cells and reduced treatment response. Studies suggest that liver metastases serve as a negative baseline factor for immunotherapy efficacy, resulting in poorer progression-free survival and objective response rates. Strategies such as liver-mediated radiotherapy may help improve treatment outcomes by reshaping the liver's immune microenvironment and reducing T-cell depletion. Understanding the complex interplay between liver metastasis and immunotherapy response is crucial for optimising patient care in GC.
